Syndax licenses UCB's preclinical CSF1R mAb

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) licensed exclusive, worldwide rights from UCB Group

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE